Market News AIOpen the app

CYTK stock news · Cytokinetics, Incorporated

Stories about Cytokinetics, Incorporated (CYTK) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CYTK

Follow Cytokinetics, Incorporated (CYTK) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CYTK
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 6:07 PM ET · Market

    Cytokinetics is giving stock options and restricted shares to new employees as part of their hiring.

    Neutral

    Cytokinetics granted options for 64,110 shares and 42,496 restricted stock units to 18 new employees. These hiring awards do not change the company's outlook.

  2. Oct 12, 2026, 7:32 AM ET · Results

    Cytokinetics shares the full details of their earnings call for the second quarter of 2026.

    Good for CYTK

    Cytokinetics reported Mycorzo sales growth, its first European launch, and successful aficamten trial results. The progress supports a brighter outlook, though regulators must still review aficamten.

  3. Aug 31, 2026, 1:59 PM ET · Trial

    Safety information from the pivotal trial is being evaluated by Cytokinetics investors.

    Neutral

    Cytokinetics announced positive primary results from its ACACIA-HCM Phase 3 clinical trial for aficamten, which showed significant improvements in symptoms and exercise performance in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, despite some concerns regarding heart failure events.

  4. Aug 28, 2026, 12:46 PM ET · Market

    A $100 investment in Cytokinetics stock a decade ago would now yield this amount.

    Neutral

    Cytokinetics has shown a strong performance over the last decade, outperforming the market with an average annual return of 21.28%, leading to significant growth in investment value.